{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:18Z","timestamp":1787071038564,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>A 69-year-old man with a history of pancreatic cancer was referred to our hospital for a newly developed solitary liver metastasis. Since the liver metastasis was in contact with the small intestine, it was necessary to perform radiation therapy while simultaneously monitoring the small intestine and liver metastasis, and then, MRI-guided stereotactic ablative radiation therapy (SABR) was performed. There were no radiation-induced adverse events during the treatment and 6 months of follow-up. MRI showed complete regression of the tumor at 6 months after SABR. It seems feasible to perform SABR safely by using MRI-guided radiation therapy system even if liver metastasis developed near the intestinal tract after surgery for pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1091_20","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T04:10:27Z","timestamp":1635912627000},"page":"S489-S492","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["MRI-guided stereotactic ablative radiation therapy for liver metastasis from pancreatic cancer"],"prefix":"10.4103","volume":"18","author":[{"given":"Yukihiro","family":"Hama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-59-20241021","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"R2-59-20241021","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","article-title":"A multi-institutional experience of MR-guided liver stereotactic body radiation therapy","volume":"4","author":"Rosenberg","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"R3-59-20241021","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/ijc.IJC_552_17","article-title":"Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?","volume":"55","author":"Ramaswamy","year":"2018","journal-title":"Indian J Cancer"},{"key":"R4-59-20241021","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-59-20241021","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-59-20241021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/jcrt.JCRT_647_16","article-title":"Role of stereotactic body radiation therapy in liver metastasis: A pilot study from tertiary cancer institute in India","volume":"15","author":"Kumar","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R7-59-20241021","doi-asserted-by":"crossref","first-page":"20160251","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1091_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:38Z","timestamp":1787067638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1091_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":7,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1091_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}